Page last updated: 2024-10-24

camostat and Cardiometabolic Syndrome

camostat has been researched along with Cardiometabolic Syndrome in 1 studies

camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.

Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.

Research Excerpts

ExcerptRelevanceReference
" Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models."8.02A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021)
" Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models."4.02A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Mizumoto, T1
Kakizoe, Y1
Nakagawa, T1
Iwata, Y1
Miyasato, Y1
Uchimura, K1
Adachi, M1
Deng, Q1
Hayata, M1
Morinaga, J1
Miyoshi, T1
Izumi, Y1
Kuwabara, T1
Sakai, Y1
Tomita, K1
Kitamura, K1
Mukoyama, M1

Other Studies

1 other study available for camostat and Cardiometabolic Syndrome

ArticleYear
A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
    Journal of pharmacological sciences, 2021, Volume: 146, Issue:4

    Topics: Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Esters; Guanidines; Hypertension; Male;

2021
chemdatabank.com